{"id":"W2077422669","doi":"10.1016/j.ygyno.2010.05.005","title":"A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)","year":2010,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Carboplatin; Erlotinib; Medicine; Ovarian cancer; Internal medicine; Oncology; Progressive disease; Chemotherapy; Epidermal growth factor receptor; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001175099,0.001492446,0.002534941,0.0005754061,0.0004183404,0.001042534,0.001051374,0.001338061,0.004610699],"category_scores_gemma":[0.0008991007,0.0007189689,0.00163904,0.0006058839,0.0009338279,0.001077609,0.0003796141,0.004112774,0.001105009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072515,"about_ca_system_score_gemma":0.001802888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002035054,"about_ca_topic_score_gemma":0.005377146,"domain_scores_codex":[0.9996562,0.0001521934,0.00001704104,0.00006254923,0.00002723486,0.00008466939],"domain_scores_gemma":[0.9993956,0.00009496139,0.00009605227,0.0000508015,0.00003338635,0.0003291958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8513717,0.05508222,0.00362307,0.0007697331,0.001604149,0.0001994987,0.0002062622,0.001898488,0.01544239,0.0002522057,0.004158724,0.06539149],"study_design_scores_gemma":[0.7112004,0.2777836,0.006305784,0.00002715435,0.0005290353,0.0001554261,0.00006043072,0.0008879983,0.001102167,0.0001239626,0.001795165,0.00002901506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905615,0.002175918,0.0003714689,0.0007087954,0.0002539094,0.00211193,0.001270682,0.00009666981,0.002449082],"genre_scores_gemma":[0.9869996,0.002385318,0.001383866,0.001030102,0.0002955679,0.00196363,0.002527498,0.00003754189,0.003376917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004610699,"threshold_uncertainty_score":0.01542431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01666574657581773,"score_gpt":0.3167443559168022,"score_spread":0.3000786093409845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}